Calcium chloride, 100 mg/mL 10 ml 10 pcs

Calcium preparations compensate for the lack of calcium ions necessary for the transmission of nerve impulses of contraction of skeletal and smooth muscles myocardial activity formation of bone tissue clotting blood coagulation process functioning of other systems and organs.

Calcium is a co-factor of many enzymes and therefore affects the secretory activity of endocrine and exocrine glands.

Decreased levels of calcium ions in the blood plasma and tissues can lead to the development of various pathological processes. Hypocalcemia leads to the development of tetany and spasmophilia impairment of skeletal and smooth muscle functions of the cardiovascular system impairment of the blood clotting system development of osteoporosis.

Calcium chloride in addition to eliminating hypocalcemia reduces vascular permeability and has anti-allergic anti-inflammatory styptic effect.

In intravenous administration stimulates the sympathetic division of the autonomic nervous system which increases release of epinephrine by the adrenal glands and has a moderate diuretic effect.

Pharmacokinetics:

Indications

– Allergic diseases (urticaria, angioedema, allergic dermatoses, serum sickness);

– hypocalcemia (including hypocalcemic tetany in hypoparathyroidism);

– lead colic;

– hyperkalemia;

– overdose of magnesium salts (as part of complex therapy).

Pharmacological effect

The calcium preparation replenishes the deficiency of calcium ions necessary for the process of transmission of nerve impulses, contraction of skeletal and smooth muscles, activity of the myocardium, formation of bone tissue, process of blood coagulation, functioning of other systems and organs.

Calcium is a co-factor for many enzymes and therefore affects the secretory activity of endocrine and exocrine glands.

A decrease in the content of calcium ions in blood plasma and tissues can lead to the development of various pathological processes. Hypocalcemia leads to the development of tetany and spasmophilia, dysfunction of the skeletal and smooth muscles of the cardiovascular system, disruption of the blood coagulation system, and development of osteoporosis.

Calcium chloride, in addition to eliminating hypocalcemia, reduces vascular permeability and has an antiallergic, anti-inflammatory hemostatic effect.

When administered intravenously, it stimulates the sympathetic part of the autonomic nervous system, enhances the release of epinephrine by the adrenal glands, and has a moderate diuretic effect.

Pharmacokinetics:

Special instructions

It cannot be administered subcutaneously or intramuscularly; tissue necrosis is possible (high concentrations of calcium chloride, starting from 5% cause severe irritation of the vascular wall).
With intravenous administration of calcium chloride, a feeling of heat appears first in the oral cavity, and then throughout the body (previously used to determine the speed of blood flow – the time between the moment of its introduction into a vein and the appearance of a feeling of heat).

Active ingredient

Calcium chloride

Composition

For 1 ml:

Active ingredient: calcium chloride hexahydrate – 100.0 mg or calcium chloride dihydrate – 67.1 mg (in terms of calcium chloride hexahydrate – 100.0 mg).

Excipients: water for injection – up to 1 ml.

Pregnancy

The use of the drug during pregnancy and breastfeeding is contraindicated.

If it is necessary to use the drug during lactation, breastfeeding should be discontinued.

Contraindications

Hypersensitivity to the components of the drug hypercalcemia severe chronic renal failure ventricular fibrillation urolithiasis hypercalciuria sarcoidosis severe atherosclerosis tendency to thrombosis simultaneous use with cardiac glycosides pregnancy breastfeeding period.

With caution:

Side Effects

From the cardiovascular system: peripheral vasodilation, decreased blood pressure, arrhythmia (including bradycardia). With rapid administration, ventricular fibrillation, cardiovascular failure, and even cardiac arrest are possible.

From the central nervous system: fainting.

From the digestive system: nausea.

From the urinary system: rarely (with impaired renal function) – hypercalcemia.

Other: there may be a feeling of heat first in the mouth and then throughout the body, a chalky taste in the mouth.

Local reactions: irritation along the vein; Skin flushing, pain, rash, calcification may indicate extravasation, which can lead to necrosis of surrounding tissue. If it enters the subcutaneous tissue or muscle, it causes severe irritation and necrosis of surrounding tissues.

Interaction

When used simultaneously, it reduces the effect of blockers of “slow” calcium channels; with other calcium- and magnesium-containing drugs, the risk of hypercalcemia or hypermagnesemia, respectively, increases, especially in patients with chronic renal failure; with quinide – intraventricular conduction may slow down and quinidine toxicity may increase.

Reduces the effectiveness of non-depolarizing muscle relaxants.

May increase the duration of action of tubocurarine chloride.

Strengthens the effect of antihistamines.

Pharmaceutically incompatible with tetracyclines magnesium sulfate and drugs containing phosphate carbonates or tartrates.

During treatment with cardiac glycosides, parenteral use of calcium chloride is not recommended due to increased cardiotoxicity.

Compatible with 5% dextrose (glucose) solution and 09% sodium chloride solution.

Overdose

Symptoms: hypercalcemia (thirst, nausea, vomiting, constipation, polyuria, abdominal pain, muscle weakness, mental disorders in severe cases – arrhythmia, coma) especially in patients with chronic renal failure.

Treatment: in case of mild overdose (calcium concentration – 26-29 mmol/l), the administration is stopped and other calcium-containing drugs are discontinued. In case of severe overdose (calcium concentration more than 29 mmol/l) – administration of 09% isotonic sodium chloride solution; non-thiazide diuretics; control of serum concentrations, if necessary, administration of potassium and magnesium preparations; control of cardiac activity; introduction of beta-blockers to prevent arrhythmias; hemodialysis.

Storage conditions

In a dry place, protected from light, at a temperature of 18 to 25 ° C. Keep out of the reach of children.

Shelf life

5 years

Manufacturer

Dalkhimfarm, Russia